Clinical Research
Please contact your provider to learn if you are eligible for any of our enrolling clinical trials.
What Participants Can Expect
Participants in our clinical trials may:
- Gain a deeper understanding of their eye condition
- Access investigational treatments that are not yet widely available
- Receive study-related eye exams at no cost (insurance is not required)
- Be closely monitored by our experienced medical and research staff
- Potentially be eligible for a modest stipend to help offset time and travel associated with participation
By participating in a clinical trial, you contribute to the development of future treatments that may benefit others living with similar conditions.
Age-Related Macular Degeneration
Eyepoint LUCIA EYP-1901-302
Office: Edison
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
4DMT 4D-150-C003
Offices: Edison & Teaneck
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1)
Artemis ADVM-022-12
Office: Teaneck
A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration
Burgundy BP41670
Office: Teaneck
A Three-Part, Phase I/II Study to Investigate the safety, tolerability, pharmacokinetics, and efficacy of zifibancimig following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery from the Port Delivery in Patients with Neovascular Age-Related Macular Degeneration.
Diabetic Retinopathy
CRIMSON – 1436-0007
Office: Teaneck
A multicenter randomized, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy
Geographic Atrophy
Astellas Reveal 3021-MA-3543
Offices: Toms River, Edison, & Teaneck
A Non-Interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Regeneron Sienna R3918-AMD-2326
A multicenter, randomized, double-masked, placebo-controlled phase 3 study of the efficacy, safety, and tolerability of subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone in participants with geographic atrophy secondary to age-related macular degeneration.